| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Cyteir Therapeutics, Inc. | 10%+ Owner | Common Stock | 3,259,025 | $5,507,752 | $1.69 | 22 Jun 2021 | By Funds |
| Cyteir Therapeutics, Inc. | 10%+ Owner | Series B Convertible Preferred Stock | 0 | 22 Jun 2021 | Direct | ||
| Cyteir Therapeutics, Inc. | 10%+ Owner | Series C Convertible Preferred Stock | 0 | 22 Jun 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| /report/000120919121042724-venrock-associates-vii-l-p-2021-06-22 | Cyteir Therapeutics, Inc. | 22 Jun 2021 | 3 | $0 | 4 | 10%+ Owner | 23 Jun 2021, 16:08 |
| /report/000120919121041806-venrock-associates-vii-l-p-2021-06-17 | Cyteir Therapeutics, Inc. | 17 Jun 2021 | 0 | $0 | 3 | 10%+ Owner | 17 Jun 2021, 21:21 |